During the past decade, Florida Cancer Institute - New Hope conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 8 clinical trials were completed, i.e. on average, 800% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Florida Cancer Institute - New Hope" #1 sponsor was "Pfizer" with 4 trials, followed by "Celgene" with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "Ascenta Therapeutics" with 1 trials sponsored and "NSABP Foundation Inc" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Florida Cancer Institute - New Hope" #1 collaborator was "US Oncology Research" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "Medivation, Inc." with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Florida Cancer Institute - New Hope" are "Breast Cancer" (3 trials), "Metastatic Breast Cancer" (3 trials), "Breast Neoplasms" (2 trials), "Advanced Breast Cancer" (1 trials) and "Advanced, Androgen Receptor Positive Triple Negative Breast Cancer" (1 trials). Many other conditions were trialed in "Florida Cancer Institute - New Hope" in a lesser frequency.

Most popular intervention types in "Florida Cancer Institute - New Hope" are "Drug" (14 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Dasatinib" (2 trials), "Enzalutamide" (2 trials), "Ixabepilone" (2 trials) and "bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Florida Cancer Institute - New Hope" are 7 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Florida Cancer Institute - New Hope". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Florida Cancer Institute - New Hope, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Florida Cancer Institute - New Hope, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".